Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Tax Provisions: 2017-2025

Historic Tax Provisions for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $873,000.

  • Ultragenyx Pharmaceutical's Tax Provisions rose 188.12% to $873,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 314.91%. This contributed to the annual value of $3.0 million for FY2024, which is 262.68% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Tax Provisions is $873,000, which was down 7.81% from $947,000 recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Tax Provisions ranged from a high of $6.3 million in Q3 2022 and a low of -$3.7 million during Q4 2023.
  • Moreover, its 3-year median value for Tax Provisions was $732,000 (2023), whereas its average is $388,545.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Tax Provisions skyrocketed by 3,354.40% in 2022 and then crashed by 2,058.73% in 2023.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Tax Provisions stood at $20,000 in 2021, then surged by 845.00% to $189,000 in 2022, then tumbled by 2,058.73% to -$3.7 million in 2023, then surged by 136.55% to $1.4 million in 2024, then spiked by 188.12% to $873,000 in 2025.
  • Its Tax Provisions was $873,000 in Q3 2025, compared to $947,000 in Q2 2025 and $1.3 million in Q1 2025.